18. Value of Patents
| Date | Source | Title | Summary | Other Categories |
| 06.2001 | Nature Medicine | Web bounty hunters chase research patients | A new internet site is seeking information on prior art to shoot down patents and subvert the highly costly legal fees involved in a professional legal search. | 19. General Patent and Biotechnology Information |
| 03.26.2001 | New York Times | Patents: A Company Receives a Software Patent and Will Soon Be Seeking Royalties | A software-based system for monitoring telephone calling patterns to detect fraud has won a patent after nine years of scrutiny at the Patent and Trademark Office. During that time, similar systems have been employed in the telecommunications industry, and the company that just won the patent says it now expects anyone using the technology to now license it and pay royalties. | 2. Patent Law |
| 02.28.2001 | Wired | Gene Patent Healthy for Introgen | A small Texas company has been granted a patent for a crucial technology used by dozens of companies for gene therapy experiments. The U.S. patent could mean that companies such as Pfizer will find themselves paying royalties to Introgen. | 19. General Patent and Biotechnology Information |
| 12.2000 | Nature Biotech | Invalidating patents | A new web-based company hopes to change the US patent system by allowing companies to post bounties of $10,000 or more in exchange for information that can either support or invalidate an existing patent. BountyQuest's vision of "market-based patent reform" permits anyone online to submit published information pertaining to a company's request for prior art-published articles or online documents about a composition of purified primate embryonic stem cells, for example. If the information is an exact match, the bounty hunter bags the prize. | 19. General Patent and Biotechnology Information |
| 07.23.2000 | New York Times | How Companies Stall Generics and Keep Themselves Healthy | Case study of deal-making between patent holding and generic pharmaceutical companies to keep generics of the market. Deals specifically with blood pressure medication Hytrin and a US anti-competition law suit. Also deals with US federal legislation extending drug patents and making it easier for generics to get to market. | 5. Economic Theory and the Economics of Patents |